Quick Answer
Whitehawk Therapeutics, Inc. reported Total Revenue of $7.15 million for the year ending 2025.
- Whitehawk Therapeutics, Inc. showed a decrease of -72.5% in Total Revenue from 2024 to 2025.
- This data is from Whitehawk Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $1.33 million | Q3 2018: $18.82 million | Q4 2018: $2.1 thousand | Q2 2020: $15.00 million | Q3 2020: $231.0 thousand | Q1 2021: $120.0 thousand | Q2 2021: $0.00 | Q3 2021: $0.00 | Q4 2021: $14.00 million | Q1 2022: $2.31 million | Q2 2022: $3.44 million | Q3 2022: $4.25 million | Q1 2023: $5.87 million | Q2 2023: $6.20 million | Q3 2023: $5.96 million | Q1 2024: $5.35 million | Q2 2024: $6.18 million | Q3 2024: $7.21 million | Q1 2025: $7.15 million | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 9 years of available data (2018 to 2025), Whitehawk Therapeutics, Inc.'s Total Revenue has declined by 64.6%.
- Historical annual values: Fiscal year 2025: $7.15 million | Fiscal year 2024: $25.98 million | Fiscal year 2023: $24.35 million | Fiscal year 2022: $15.22 million | Fiscal year 2021: $14.00 million | Fiscal year 2020: $14.00 million | Fiscal year 2020: $14.00 million | Fiscal year 2019: $0.00 | Fiscal year 2018: $20.16 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: